Cargando…

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future

Dysfunction of the gastrointestinal tract has now been recognized to affect all stages of Parkinson’s disease (PD). The consequences lead to problems with absorption of oral medication, erratic treatment response, as well as silent aspiration, which is one of the key risk factors in developing pneum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray Chaudhuri, K, Qamar, Mubasher A, Rajah, Thadshani, Loehrer, Philipp, Sauerbier, Anna, Odin, Per, Jenner, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516582/ https://www.ncbi.nlm.nih.gov/pubmed/28725704 http://dx.doi.org/10.1038/npjparkd.2016.23

Ejemplares similares

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Author Correction: Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, M. A., et al.
Publicado: (2023)

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease
por: van Wamelen, Daniel J., et al.
Publicado: (2018)

The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence
por: Kurtis, Mónica M, et al.
Publicado: (2017)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
por: Leta, Valentina, et al.
Publicado: (2021)

Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected
por: Todorova, Antoniya, et al.
Publicado: (2014)

The Dashboard Vitals of Parkinson’s: Not to Be Missed Yet an Unmet Need
por: Chaudhuri, Kallol Ray, et al.
Publicado: (2022)

Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale
por: Martinez-Martin, Pablo, et al.
Publicado: (2017)

Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
por: Cedergren Weber, Gustav, et al.
Publicado: (2023)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
por: Tall, P., et al.
Publicado: (2023)

Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
por: Rota, Silvia, et al.
Publicado: (2022)

The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review
por: Zis, Panagiotis, et al.
Publicado: (2015)

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
por: Qamar, Mubasher A., et al.
Publicado: (2023)

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
por: Jost, Stefanie T., et al.
Publicado: (2021)

SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
por: Boura, Iro, et al.
Publicado: (2023)

Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review
por: Smilowska, Katarzyna, et al.
Publicado: (2021)

Gender gap in deep brain stimulation for Parkinson’s disease
por: Jost, Stefanie T., et al.
Publicado: (2022)

Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
por: Sportelli, Carolina, et al.
Publicado: (2020)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Advances in non-dopaminergic treatments for Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

Editorial: Non-Dopaminergic Systems in Parkinson’s Disease
por: Miguelez, Cristina, et al.
Publicado: (2020)

Dopaminergic Medication Increases Reliance on Current Information in Parkinson’s Disease
por: Vilares, Iris, et al.
Publicado: (2017)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need
por: Ray Chaudhuri, Kallol, et al.
Publicado: (2013)

Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease
por: Sauerbier, Anna, et al.
Publicado: (2021)

Correction: A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need
por: Ray Chaudhuri, Kallol, et al.
Publicado: (2016)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
por: Raeder, Vanessa, et al.
Publicado: (2021)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future
por: Jenner, Peter
Publicado: (2015)

Learning from the past and expecting the future in Parkinsonism: Dopaminergic influence on predictions about the timing of future events
por: Tomassini, Alessandro, et al.
Publicado: (2019)

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Ethnic Disparities in Treatment of Chronic Pain in Individuals with Parkinson's Disease Living in the United Kingdom
por: Rukavina, Katarina, et al.
Publicado: (2022)

Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study
por: Sauerbier, Anna, et al.
Publicado: (2018)

Non-Dopaminergic Therapies
por: Nutt, John G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hlmj67bhur0edg3ehcpuspuaqb